Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients With Advanced Lung Cancer
A Single-arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte (GT201 Injection ) for Treatment of Patients With Advanced Lung Cancer
Sponsor: Grit Biotechnology
Terminated
The study was terminated from a business perspective.
Other terminated trials from Grit Biotechnology
Other Adult trials with similar outcome
This observational or N/A phase trial investigates Adult and Lung Cancer and is currently terminated or withdrawn. Grit Biotechnology leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
4 versions recorded-
Apr 28, 2026 — Present [daily]
Terminated
Status: Recruiting → Terminated · Phase: NA → None
-
Mar 2025 — Apr 2026 [monthly]
Recruiting NA
-
Sep 2024 — Mar 2025 [monthly]
Recruiting NA
-
Aug 2024 — Sep 2024 [monthly]
Recruiting NA
First recorded
Jul 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT201 injection ) for treatment of patients with Advanced lung cancer,while evaluating pharmacokinetic characteristics and efficacy assessment.
Contact Information
- Grit Biotechnology
For direct contact, visit the study record on ClinicalTrials.gov .